Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.
How this was made
The 30-second read
Why it matters
The data could accelerate Phase 3 enrollment and improve valuation, but execution risk remains.
Market read
First‑time disclosure of robust Phase 2 results for a novel ADC in a high‑unmet‑need cancer indication.
What to watch
The trial enrolled heavily pre‑treated patients; real‑world effectiveness and reimbursement pathways remain uncertain.
Background
Genmab is a Copenhagen‑based biotech with several approved antibodies and a pipeline of ADCs targeting folate‑receptor alpha.
Ticker impact
Genmab announced Phase 2 RAINFOL-01 trial results showing 45.9% ORR and 12.1‑month median duration of response in platinum‑resistant ovarian cancer.
upward pressure as market incorporates strong efficacy and durability signals
Objective response rate above 40% and durable responses in a hard‑to‑treat population are materially better than historical ADC benchmarks, suggesting a meaningful commercial opportunity.
Market effects
Strengthens the oncology ADC subsector and may boost peer biotech valuations.
European biotech markets could see modest gains as a Copenhagen‑based firm reports breakthrough data.
Adds to the pipeline of FRα‑targeted therapies, influencing global cancer‑treatment investment themes.
Counterpoint
If safety concerns emerge in later phases, the early efficacy may be overstated, limiting upside.
Key entities
- companyGenmab A/S
International biotech developing antibody‑drug conjugates.
- eventInternational Gynecologic Cancer Society (IGCS) Congress 2026
Venue where the trial results were presented.
